Posters & Publications
Sample Size Re-Estimation in an Ongoing Dose-Ranging Study of Nalbuphine Extended-Release for Cough in Idiopathic Pulmonary Fibrosis: The CORAL Study
Maher et al., poster presentation at the 13th International Symposium on Cough (2024).
Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Refractory Chronic Cough: A Phase 2 Trial in Progress
Smith et al., poster presentation at the 13th International Symposium on Cough (2024).
Association of pruritus and chronic cough: an all of us database study
Sharma et al., Journal of Dermatological Treatment (2024).
Nalbuphine Oral Extended-Release Tablets Reduce Cough Bouts in Patients With Idiopathic Pulmonary Fibrosis
Smith et al., poster presentation at the American Thoracic Society (ATS) 2024 International Conference.
Efficacy of Oral Nalbuphine Extended Release in Patients With Idiopathic Pulmonary Fibrosis Related Chronic Cough: a Phase 2 Study
Maher et al., as presented orally at the American Thoracic Society (ATS) 2023 International Conference.
Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis
Maher TM et al., NEJM Evidence (2023).
Utility of EXACT, a patient-reported outcome instrument, for idiopathic pulmonary fibrosis-related cough
Wijsenbeek et al., poster presentation at the 2023 European Respiratory Society (ERS) International Congress.
The Effect of Oral Nalbuphine Extended Release on Patient-Reported Outcome Measures in Patients With Idiopathic-Pulmonary-Fibrosis-Related Chronic Cough
Maher et al., poster presentation at the American Thoracic Society (ATS) 2023 International Conference.
Efficacy of Oral Nalbuphine Extended Release in Patients With Idiopathic Pulmonary Fibrosis Related Chronic Cough: a Phase 2 Study
Maher et al., poster presentation at the American Thoracic Society (ATS) 2023 International Conference.
Efficacy of oral nalbuphine extended release for the treatment of chronic cough in idiopathic pulmonary fibrosis: data analysis of a phase 2 study
Molyneaux et al., as presented orally at the British Thoracic Society (BTS) Winter Meeting 2022.
An interim analysis of a phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis
Maher et al., poster presentation at the 21st International Colloquium on Lung and Airway Fibrosis (ICLAF) 2022.
An interim analysis of a phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis
Maher et al., as presented orally at the 2022 European Respiratory Society (ERS) International Congress.
The Role of Kappa-Opioid and Mu-Opioid Receptors in Pruritus: Peripheral and Central Itch Circuits
Kim BS et al., Exp Dermatol. (2022).
Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications
Elmariah et al., Journal of the American Academy of Dermatology (JAAD) International (2021).
Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase
Weisshaar E. et al., Journal of The European Academy of Dermatology and Venereology (2021).
Prevalence, Incidence, and Presence of Comorbidities in Patients with Prurigo and Pruritus in Germany: A Population-Based Claims Data Analysis
Augustin et al., Journal of The European Academy of Dermatology and Venereology (2021).
Safety and Pharmacokinetics of Nalbuphine Following Administration of Nalbuphine ER Tablets in Subjects With Impaired Hepatic Function
Rohatagi S. et al., Poster Presentation at European Society for Dermatological Research (ESDR) 50th Annual Meeting (2021).
The Role of Kappa- and Mu- Opioid Receptors in Pruritus
as presented at Maui Derm for Dermatologists 2021.
Modulation of the Mu and Kappa Opioid Axis for Treatment of Chronic Pruritus
as presented at Maui Derm for Dermatologists 2021.
Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis
Ständer et al., The American Academy of Dermatology (JAAD) International (2020).
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus
as presented at the 2020 Fall Clinical Dermatology Conference.
Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open-Label Extension Phase
as presented at the 2020 Fall Clinical Dermatology Conference.
Prevalence of Prurigo Nodularis in Poland
Reich and Ryczek, Acta Dermato Venereologica (2020).
Prevalence of Prurigo Nodularis in the United States: Findings of a Retrospective Database Analysis
as presented at the 2020 AAD Annual Meeting.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus
Mathur et al., American Journal of Nephrology (2017)
Nalbuphine ER Tablets in Hemodialysis Patients with Severe Uremic Pruritus: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
as presented at the National Kidney Foundation Spring 2016 Meeting.
Long-Term Effects of Nalbuphine ER Tablets in Hemodialysis Patients with Uremic Pruritus: A Multicenter Open-Label Trial
as presented at the National Kidney Foundation Spring 2016 Meeting.
Isolation, Characterization, and Synthesis of N-(4-Hydroxy-3-Methylene-Butanoic Acid) Nornalbuphine, a Previously Unidentified Nalbuphine Metabolite
Thornquest et al., poster presented at AAPS Annual Meeting (2015).
Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus
Hawi et al., BMC Nephrology (2015).
Pharmacokinetics of nalbuphine hydrochloride proof-of-concept study with pharmacokinetics demonstrating anti-pruritic activity of oral nalbuphine in hemodialysis patients with uremic pruritus
as presented at the 2014 Meeting of the Society for Investigative Dermatology.
Pharmacokinetics of Nalbuphine Hydrochloride Extended Release Tablets in Hemodialysis and Healthy Subjects following Multiple Escalating Oral Doses
as presented at the 2014 Meeting of the American College of Pharmacology.
Exploring Clinical and Pharmacological Effects of Nalbuphine HCl Oral Tablets in Hemodialysis Subjects with Pruritus
as presented at American Society of Nephrology’s 2014 Kidney Week.
Nalbuphine attenuates itch in the substance P-induced mouse model
as presented at 7th World Congress on Itch (2013).